Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Future Innovation in Oncology: Update Bulletin # 2 [January 2019]

Product Code:
596201272
Publication Date:
January 2019
Format:
PDF
Price:
$1,315

This edition presents key opinion leader (KOL) views on data presentations given at American Society of Hematology’s Annual Meeting 2018 (ASH 2018), held in December 2018. Topics covered include: Regeneron’s new data for REGN1979 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma, including promising clinical results in follicular lymphoma and diffuse large B-cell lymphoma; Celgene’s results from the TRANSCEND-CLL-004 trial assessing JCAR017 in patients with relapsed/refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma; Kite’s updated results from the ZUMA-3 trial of KTE-X19 in adults with relapsed/refractory acute lymphoblastic leukaemia.

Business Questions:

• What are the experts reactions to the results of REGN1979’s Phase I dose-finding trial in relapsed or refractory non-Hodgkin’s lymphoma?
• According to KOLs, what are the likely next steps for the development of REGN1979?
• What are KOLS opinions on the Phase I data from the TRANSCEND-CLL-004 study?
• What is the potential of JCAR017 as a future treatment for chronic lymphocytic leukaemia, as a monotherapy and/or in combination with ibrutinib (Imbruvica; AbbVie/Janssen)?
• Where will JCAR017 fit in the treatment paradigm for chronic lymphocytic leukaemia?
• What are KOLs opinions of the results of KTE-X19 in the ZUMA-3 trial in adults with relapsed or refractory acute lymphoblastic leukaemia?
• How does KTE-X19’s safety profile compare to other therapies?




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved